Citations

Mayo Clinic

Showing 10 of 108523 citations.

Symptomatic therapy in multiple sclerosis: Big pharma should do more—YES
Sıva, Aksel , Kantarci, Orhun H. , Siva, Aksel

Multiple Sclerosis Journal | June 17, 2015 | Volume: 21 | Issue: 8 | Pages: 980-982

10.1177/1352458515588974 | PMID 26084347 Get It

When instability is a good thing
Dronca, Roxana

Science Translational Medicine | June 17, 2015 | Volume: 7 | Issue: 292 | Pages: No page available

10.1126/scitranslmed.aac7154 Get It

Mismatch repair–deficient tumors have a high rate of somatic mutations, have higher neoantigen formation, and are more sensitive to immune checkpoint blockade.
Epidemiology of amyotrophic lateral sclerosis in Minnesota: A year-long population based study
Harper, Caitlin J., Sorenson, Eric J. , Mandrekar, Jay

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | June 17, 2015 | Volume: 16 | Issue: 7-8 | Pages: 520-523

10.3109/21678421.2015.1051991 | PMID 26083871 Get It

Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice
Pestana, L., Becker, Brandon , Loftus, Edward V. , Hanson, Karen A., Bruining, David H. , Tremaine, William J., Kane, Sunanda V. , Moon, Won Kyu , Loftus, Edward V

Alimentary Pharmacology & Therapeutics | June 17, 2015 | Volume: 42 | Issue: 4 | Pages: 428-440

10.1111/apt.13288 | PMID 26081839 Get It

SummaryBackgroundCertolizumab pegol (CZP) is Food and Drug Administration (FDA)‐approved to treat Crohn's disease (CD). However, the efficacy and safety of CZP outside clinical trials are not well established.AimTo report the efficacy, safety and predictors of response to CZP in CD patients treated during a 6‐year period since FDA‐approval at a tertiary care centre.MethodsAll CD patients who received CZP at our institution between 2008 and 2013 were evaluated through retrospective medical record‐based review of steroid‐free complete response (SCR), loss of response and safety.ResultsA total of 358 patients were included. One hundred twelve patients (31.3%) and 189 (52.8%) received CZP as their second and third biological agent, respectively. The probability of SCR at 26 week was 19.9% (95% CI, 15.9–24.5). The probability of survival free of loss of response at 2 year was 45.7% (95% CI, 32.5–59.5). A predictor of SCR was age at CD diagnosis of >40 years old (hazard ratio, HR relative to those <17, 4.69; 95% CI, 1.75–12.61). Negative predictors included present perianal fistula (HR, 0.39; 95% CI, 0.16–0.98) and prior primary nonresponse to adalimumab (ADA; HR relative to secondary loss of response, 0.18; 95% CI, 0.04–0.76). Twenty‐three patients (6.4%) experienced serious adverse events and 19 patients (5.3%) discontinued CZP due to adverse events.ConclusionsCertolizumab pegol was both effective and well tolerated for the treatment of Crohn's disease in this large tertiary care centre enriched with biologics‐exposed patients. It may be more effective in patients without early‐aged Crohn's disease diagnosis, prior primary nonresponse to adalimumab and present perianal fistula.
Impact of Freezing Time and Balloon Size on the Thermodynamics and Isolation Efficacy During Pulmonary Vein Isolation Using the Second Generation Cryoballoon
Takami, Mitsuru , Misiri, Juna, Parker, Kay D., Sarmiento, Ray I., Johnson, Susan B., Packer, Douglas L. , Lehmann, H. Immo

Circulation: Arrhythmia and Electrophysiology | June 17, 2015 | Volume: 8 | Issue: 4 | Pages: 836-845

10.1161/circep.115.002725 | PMID 26082516 Get It

Background— The differences in ablation characteristics of freezing time and balloon size using second generation cryoballoon are still unknown. Methods and Results— Twenty-six dogs underwent pulmonary vein (PV) isolation. Balloon and tissue temperatures (left atrial–PV junction, phrenic nerve, and internal esophagus) were monitored. The ablation duration was randomized to either 3 or 4 minutes, which did not show significant differences in temperature profiles, PV isolation success rate, complications, or histological changes. Twenty dogs underwent cryoablation using 28-mm cryoballoon, 6 dogs were done using the 23-mm cryoballoon. Positioning of the 23-mm cryoballoon was more distal in the PV, which resulted in better PV occlusion. Temperature profiles showed lower temperatures in the 23-mm cryoballoon than in the 28-mm cryoballoon (inner balloon, median [range]: −51.5 [−66.0 to −31.0] versus −43.0 [−64.0 to −26.0]°C, P <0.001; balloon surface: −43.0 [−60.0 to −15.8] versus −6.5 [−46.2 to 28.9]°C, P <0.001; left atrial–PV junction: −6.7 [−20.0 to 21.4] versus 15.8 [−14.4 to 35.1]°C, P <0.001), and trended toward a higher PV isolation success rate in the 23-mm cryoballoon. Histologically, deeper extensions of ablative lesions into the PV were seen with 23-mm cryoballoon, and larger ablative lesions were seen in the left atrial antrum using 28-mm cryoballoon. Conclusions— The efficacy of 3-minute ablation was not significantly different from 4-minute ablation in dogs. The 23-mm cryoballoon had a greater cooling effect than the 28-mm cryoballoon for small PVs, but showed narrower ablative lesions in the left atrial antrum.
Letter: underutilisation of albumin infusion in high-risk spontaneous bacterial peritonitis
Peeraphatdit, Thoetchai , Gulleen, Elizabeth , Skarda, Paula, Anderson, K. B., Chaiteerakij, Roongruedee

Alimentary Pharmacology & Therapeutics | June 17, 2015 | Volume: 42 | Issue: 2 | Pages: 241-242

10.1111/apt.13252 | PMID 26081688 Get It

Atrioventricular Nodal Block With Atrioventricular Nodal Reentrant Tachycardia Ablation
Asirvatham, Samuel J. , Stevenson, William G. , Asirvatham, Samuel J

Circulation: Arrhythmia and Electrophysiology | June 16, 2015 | Volume: 8 | Issue: 3 | Pages: 745-747

10.1161/circep.115.002989 | PMID 26082531 Get It

123 I- Meta -Iodobenzylguanidine Guanidine–Guided Ventricular Tachycardia Ablation
Aggarwal, Niti R., Chareonthaitawee, Panithaya

Circulation: Arrhythmia and Electrophysiology | June 16, 2015 | Volume: 8 | Issue: 3 | Pages: 520-522

10.1161/circep.115.002905 | PMID 26082523 Get It

Global and local ancestry in African‐Americans: Implications for Alzheimer's disease risk
Hohman, Timothy J. , Bailey, Jessica N. Cooke , Reitz, Christiane , Jun, Gyungah , Beecham, Gary W. , Carney, Regina M., Vance, Jeffery M. , Rajbhandary, Ruchita, Lin, Chiao‐Feng , Larson, Eric B., Graff‐Radford, Neill R. , Evans, Denis A., Jager, Philip L. De , Crane, Paul K. , Buxbaum, Joseph D. , Murrell, Jill R. , Raj, Towfique , Ertekin‐Taner, Nilüfer , Baldwin, Clinton T., Green, Robert C. , Barnes, Lisa L. , Cantwell, Laura B., Fallin, M. Daniele , Go, Rodney C.P., Griffith, Patrick , Obisesan, Thomas O. , Lunetta, Kathryn L. , Kamboh, M. Ilyas , Bennett, David A. , Hardy, John , Hendrie, Hugh C. , Hall, Kathleen, Goate, Alison , Lang, Rosalyn, Byrd, Goldie S. , Kukull, Walter A. , Farrer, Lindsay A. , Martin, Eden R. , Pericak‐Vance, Margaret A. , Schellenberg, Gerard D. , Mayeux, Richard , Haines, Jonathan L. , Thornton‐Wells, Tricia A., Carroll, Steven L. , Bennett, David A. , Naj, Adam Christian , Liu, Zhi , Cuccaro, Michael L. , Vardarajan, Badri Narayan , Wang, Weixin , Valladares, Otto , Logue, Mark W. , Manly, Jennifer J. , López, Oscar L. , Foroud, Tatiana , Seto, Mabel , Hardy, John , Goate, Alison M , Barnes, Lisa L

Alzheimer's & Dementia | June 16, 2015 | Volume: 12 | Issue: 3 | Pages: 233-243

10.1016/j.jalz.2015.02.012 | PMID 26092349 Get It

AbstractIntroductionAfrican‐American (AA) individuals have a higher risk for late‐onset Alzheimer's disease (LOAD) than Americans of primarily European ancestry (EA). Recently, the largest genome‐wide association study in AAs to date confirmed that six of the Alzheimer's disease (AD)‐related genetic variants originally discovered in EA cohorts are also risk variants in AA; however, the risk attributable to many of the loci (e.g., APOE, ABCA7) differed substantially from previous studies in EA. There likely are risk variants of higher frequency in AAs that have not been discovered.MethodsWe performed a comprehensive analysis of genetically determined local and global ancestry in AAs with regard to LOAD status.ResultsCompared to controls, LOAD cases showed higher levels of African ancestry, both globally and at several LOAD relevant loci, which explained risk for AD beyond global differences.DiscussionExploratory post hoc analyses highlight regions with greatest differences in ancestry as potential candidate regions for future genetic analyses.
Functional neuroimaging correlates of thinking flexibility and knowledge structure in memory: Exploring the relationships between clinical reasoning and diagnostic thinking
Durning, Steven J. , Costanzo, Michelle E. , Beckman, Thomas J. , Artino, Anthony R. , Roy, Michael J. , Vleuten, Cees van der , Holmboe, Eric S. , Lipner, Rebecca S. , Schuwirth, Lambert

Medical Teacher | June 16, 2015 | Volume: 38 | Issue: 6 | Pages: 570-577

10.3109/0142159x.2015.1047755 | PMID 26079668 Get It